Innerer Wert von S&P & Nasdaq Kontaktieren

Deinove S.A. DNVVF OTC

Other OTC • Healthcare • Biotechnology • FR • USD

SharesGrow Intrinsic Value
N/A
Negative cash flow

Deinove S.A. (DNVVF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Grabels, France. Der aktuelle CEO ist Alexis Rideau.

DNVVF hat IPO-Datum 2013-12-02, 44 Vollzeitbeschäftigte, gelistet an der Other OTC.

Über Deinove S.A.

DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME Oléoactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioMérieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Oléos-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.

📍 Cap Sigma, Grabels 34790 📞 33 4 48 19 01 00
Unternehmensdetails
SektorGesundheitswesen
BrancheBiotechnologie
LandFrance
BörseOther OTC
WährungUSD
IPO-Datum2013-12-02
CEOAlexis Rideau
Mitarbeiter44
Handelsinformationen
Aktueller Kurs$0.50
52-Wochen-Spanne0.4706-0.58
Beta0.35
ETFNein
ADRNein
Kontaktieren
🎓
SharesGrow Akademie
Lernen Sie inneren Wert zu berechnen und unterbewertete Aktien zu finden.
Wöchentliche Live-Sessions
Nachricht senden